First drug approved in 2021

Poxel is developing a pipeline of several mid-to-late-stage drug candidates targeting the mitochondrial dysfunction. Imeglimin was approved as TWYMEEG® for type 2 diabetes in Japan in June 2021 and was launched in September 2021. Imeglimin has also successfully completed Phase 2 development in the U.S. and EU. PXL770 and PXL065 are in mid-stage development for NASH. We are also evaluating our AMPK activation and TZD platforms for other chronic and rare metabolic diseases with the objective to launch Phase 2a proof-of-concept studies in ALD mid-2022.

VIEW OUR CANDIDATES

Latest News

Poxel Announces Results from June 21, 2022 Ordinary Annual and Extraordinary General Meeting

Shareholders approved all proposed resolutions LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic…

Read this Press Release: Poxel Announces Results from June 21, 2022 Ordinary Annual and Extraordinary General Meeting

Poxel Announces New Solid Form Patent for PXL065 that Provides Additional Protection through 2041

Results of PXL065 Phase 2 (DESTINY-1) trial in NASH expected in Q3 2022 LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing…

Read this Press Release: Poxel Announces New Solid Form Patent for PXL065 that Provides Additional Protection through 2041

Poxel Announces its Participation in Upcoming Investor and Scientific Conferences

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology,…

Read this Press Release: Poxel Announces its Participation in Upcoming Investor and Scientific Conferences
Click here to show the previous slide Click here to show the next slide

Innovative Pipeline of First-In-Class Products

Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for NASH and rare metabolic diseases.

View Pipeline
Innovative Pipeline of First-In-Class Products

Targeting Mitochondrial Dysfunction

Imeglimin was approved as TWYMEEG® for type 2 diabetes in Japan in June 2021 and will be marketed by our strategic partner, Sumitomo Dainippon Pharma, in 2021. Imeglimin has successfully completed Phase 2 development in the U.S. and EU. PXL770 and PXL065 are in mid-stage development for NASH. We are also evaluating our AMPK activation and TZD platforms for other chronic and rare metabolic diseases.

View Our Candidates
Targeting Mitochondrial Dysfunction

Backed by Strong Leadership

Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.

Meet Our Team
Backed by Strong Leadership